Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 159,700 shares, a growth of 19.8% from the November 30th total of 133,300 shares. Based on an average daily volume of 586,100 shares, the short-interest ratio is currently 0.3 days. Currently, 0.3% of the shares of the company are sold short.
Sio Gene Therapies Stock Performance
NASDAQ SIOX remained flat at $0.44 on Friday. 1,059,849 shares of the company's stock traded hands. Sio Gene Therapies has a twelve month low of $0.23 and a twelve month high of $1.53. The stock's fifty day moving average price is $0.34 and its 200-day moving average price is $0.34.
Get Sio Gene Therapies alerts:Sio Gene Therapies (NASDAQ:SIOX – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.04) EPS for the quarter.
Institutional Investors Weigh In On Sio Gene Therapies
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in Sio Gene Therapies in the second quarter valued at about $33,000. SVB Wealth LLC acquired a new stake in shares of Sio Gene Therapies during the third quarter worth about $26,000. Clearline Capital LP lifted its position in shares of Sio Gene Therapies by 79.7% during the first quarter. Clearline Capital LP now owns 392,691 shares of the company's stock worth $263,000 after purchasing an additional 174,185 shares in the last quarter. Finally, Rubric Capital Management LP increased its stake in shares of Sio Gene Therapies by 16.5% during the third quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock worth $1,960,000 after buying an additional 988,995 shares during the period.About Sio Gene Therapies
(Get Rating)
Sio Gene Therapies Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM.
Read More
- Get a free copy of the StockNews.com research report on Sio Gene Therapies (SIOX)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.